When the RANK protein was suppressed in luminal cells of the breast tissue in female mice, they did not produce milk in their first pregnancy.
ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new early detection technology for Alzheimer’s disease (AD) and has successfully closed a €5.4 million equity round.
The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round Read More »
The study has been published in the journal Nature Medicine, one of the most prestigious in Medicine, and represents a step forward to address an important health challenge worldwide, with high rates of therapeutic failure and mortality.
Research led in Bellvitge will allow progress in the fight against bacteremia Read More »
The study performs an evaluation to determine the cost-effectiveness and profitability of two strategies for the early detection of endometrial cancer in women with postmenopausal bleeding.
1 in 3 men over the age of 15 are infected with at least one genital human papillomavirus (HPV) type, and 1 in 5 are infected with one or more of what are known as high risk, or oncogenic, HPV types
One in three men worldwide are infected with genital human papillomavirus Read More »
A research team led by Aurora Pujol and Dr. Carlos Casasnovas developed an innovative computational algorithm called ClinPrior. This algorithm demonstrated its ability to improve the diagnosis rate in patients with rare diseases of genetic origin.
A new clinical algorithm increases the diagnosis rate of rare diseases Read More »
This work, in which IDIBELL and the Catalan Institute of Oncology (ICO) participated, has analyzed the concentrations of nicotine in the air, as well as, cotinine and nitrosamines, specifically of tobacco dust in vehicles.
Study shows the health risk of smoking in the car Read More »
This study has found significant relationships between the blood concentration of two endocannabinoid neurotransmitters with clinical variables and body mass index (BMI) in a group of patients with extreme clinical weight conditions.
The results show that a protein, NADPH oxidase NOX4, which had been described as a mediator of TGF-beta-induced cell death, also participates in the pro-tumorogenic response to this factor, specifically mediating its pro-migratory and invasive effects.
According to the study carried out by the IDIBELL research group on cardiovascular diseases (BIOHEART), this program not only could reduce hospital admissions and deaths of patients 30 days after discharge – as it was already proven – but also at 90 and 180 days.
